Sabin Inactivated Poliovirus Vaccine Description
Sabin Inactivated Poliovirus Vaccine (IPV) is a liquid trivalent vaccine produced from Sabin poliovirus type 1, 2, and 3 strains grown on Vero cells.
In 1988, the World Health Assembly adopted a goal of global polio eradication. Since then, polio incidence has decreased by more than 99%, using oral polio vaccine (OPV, Sabin vaccine) and IPV (Salk vaccine) to interrupt transmission.
OPV has the benefits of lower cost compared with IPV and better induction of intestinal/mucosal immunity. It is also associated with vaccine-associated paralytic polio and vaccine-derived poliovirus infections, which have outnumbered wild-type polio infections in recent years.
Sabin Inactivated Poliovirus Vaccine Indication
This vaccine is indicated to prevent the Wild Polio Virus in the hope of completely eradicating the disease.
Sabin Inactivated Poliovirus Vaccine Dosage
The vaccine is administered as three intramuscular injections on (0.5ml) Day 0, Day 30, and Day 60, respectively, and a single intramuscular injection of vaccine (0.5 ml) at 18 months.
Sabin Inactivated Poliovirus Vaccine News
September 1, 2019 - The sIPV is noninferior compared with IPV. Both demonstrate a good safety profile.
April 8, 2019 - The results of this study were published in The Journal for Infectious Diseases. This analysis revealed that the studied sIPV demonstrated an immunogenicity profile non-inferior to that of the conventional IPV and a good safety profile.
Sabin Inactivated Poliovirus Vaccine Clinical Trial
Phase 3 NCT03526978: An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants
- The study is a randomized, double-blind, controlled randomized, double-blind, controlled clinical trial.
- The purpose of this study is to evaluate the immunogenicity and safety of Sabin Inactivated Poliovirus Vaccine (Vero cell) manufactured by Sinovac Vaccine Technology Co., Ltd in 2-month-old infants.
- The control vaccine is a commercialized Inactivated Poliovirus Vaccine manufactured by Sanofi Pasteur company. 1200 healthy infants between 60-90 days will be randomly assigned into an experimental group or control group in the ratio 1:1.